Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Prior Auth Coverage | Ope…
    Ask Trek AI about this page
    Currentpriority healthPolicy 26328

    Priority Health Medicare Prior Authorization Criteria — Pharmacy & Specialty Drugs

    Customize your policy alerts

    Sign up for priority health Policy 26328 alerts

    Get alerted when Policy 26328 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare prior authorization criteria for pharmacy and specialty drugs for Priority Health members, organized alphabetically by drug with indication-specific requirements, exclusions, documentation, duration, and utilization controls.

    Policy Summary
    Payerpriority health
    PolicyMedicare prior authorization criteria — pharmacy & specialty drugs
    Policy CodePolicy 26328
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit required prior-therapy documentation and diagnosis confirmation per product-specific criteria when requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Alphabeticalorganization
    1-2 yearstypical duration
    Documentation requiredprior therapy
    Oftenspecialist prescriber

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Some
    explicit exclusions

    Per-Product Coverage Criteria (Alphabetical Index)

    ACTHAR — initial and reauthorization requirements

    ACTHAR coverage when ALL of the following are met:

    ACTHAR: documentation and limits: Documentation of prior therapies and responses required; quantity limited to FDA-supported dosing; coverage duration 6 weeks; not covered for acute gouty arthritis, severe psoriasis, and atopic dermatitis; for all covered indications except infantile spasms must have a therapeutic trial of a parenteral glucocorticoid AND Cortrophin

    Reauthorization requires demonstrated clinical benefit.

    Adalimumab and related biologics

    Adalimumab-class biologics covered when ALL of the following are met:

    Biologic exclusions: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors

    Prescriber should be a specialist or have consulted a specialist; documentation of prior therapies and responses required; indication‑specific prior trials required (e.g., RA: trial/failure of traditional non‑biologic immunomodulator; AS: trial/failure of an NSAID; psoriasis: trial/failure of a traditional non‑biologic immunomodulator).

    Aimovig — migraine prevention

    Aimovig coverage when ALL of the following are met:

    Aimovig initial: For migraine prevention initial requests: at least four migraine days per month; must not be used with other CGRP antagonist therapy>= 4 migraine days/month

    Initial approval 1 year; reauthorization 2 years; reauthorization requires documentation of decreased migraine days per month; dosing must align with FDA labeling.

    Amvuttra — hATTR-PN and ATTR-CM

    Amvuttra coverage differs by indication and requires ALL listed criteria:

    hATTR‑PN initial: Patient has a transthyretin (TTR) mutation AND baseline polyneuropathy disability (PND) score ≤ IIIb AND clinical signs and symptoms of polyneuropathy documented in medical records

    Prescriber documentation required; reauthorization requires demonstration of positive clinical response vs baseline; initial and reauth coverage duration one year.

    ATTR‑CM initial: Trial with failure, intolerance, or contraindication to tafamidis AND NYHA class I–III heart failure with clinical manifestations or prior HF hospitalization AND ECHO or CMR demonstrating cardiac involvement AND diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging; if radionuclide imaging used require Grade 2 or 3 cardiac uptakeNYHA class I–III

    Will not be approved for primary (light‑chain) amyloidosis; reauthorization requires documentation of clinical response; initial and reauth one year.

    Arikayce — MAC lung disease

    Arikayce coverage when ALL of the following are met:

    Arikayce initial: Sputum culture supporting Mycobacterium avium complex (MAC) lung disease diagnosis AND documentation of failure to obtain negative cultures after a minimum of 6 months of appropriate multidrug background regimen

    Must be prescribed by or in consultation with an infectious disease specialist or pulmonologist; initial approval 6 months; reauthorization 12 months and requires a negative sputum culture within the last 30 days.

    Benlysta — SLE and lupus nephritis

    Benlysta coverage when ALL of the following are met:

    SLE initial: SELENA‑SLEDAI score ≥6 AND either anti‑dsDNA >30 IU/mL OR ANA >1:80 AND patient is taking two of the following together for ≥12 weeks: steroid, immunosuppressant, and/or hydroxychloroquineSELENA‑SLEDAI ≥6

    Prescriber must be a specialist or have consulted a specialist; initial duration 1 year; reauthorization 2 years with evidence of clinical improvement.

    Lupus nephritis initial: Confirmed SLE AND kidney biopsy confirming class 3, 4 and/or 5 disease AND receiving standard therapy for LN (e.g., mycophenolate or azathioprine plus steroid)

    Reauthorization requires evidence of clinical improvement including improved or stable eGFR.

    BRAFTOVI initial therapy

    BRAFTOVI and brivaracetam initial therapy requirements:

    BRAFTOVI approval: Documentation of BRAF V600 mutation status

    Coverage duration two years; applies to indicated malignancies.

    Brivaracetam approval: Documentation of trial and failure with generic levetiracetam AND at least one other generic anticonvulsant (failure = inadequate seizure control)

    Prerequisite therapy required; coverage duration two years.

    Brivaracetam initial therapy

    Brivaracetam (oral formulations) coverage when ALL of the following are met:

    Brivaracetam approval: Documentation of trial and failure with generic levetiracetam AND at least one other generic anticonvulsant (failure = inadequate seizure control)

    Coverage duration two years; prerequisite therapy required.

    Colistimethate criteria

    Colistimethate sodium covered when ALL of the following are met:

    Colistimethate approval: Used IV or IM only (nebulization/inhalation not covered) AND infection proven or strongly suspected to be caused by susceptible bacteria with culture and susceptibility OR supporting local epidemiology/susceptibility patterns

    Must be prescribed by or in consultation with an infectious disease specialist; coverage duration one year.

    CORTROPHIN coverage

    CORTROPHIN coverage when ALL of the following are met:

    CORTROPHIN initial approval: Initial use per FDA label or max 3 months if unspecified AND indication‑specific prerequisite trials as required (e.g., parenteral plus oral glucocorticoid for MS exacerbation); infantile spasms exempt

    Quantity limited to FDA‑supported dosage; reauthorization requires demonstrated clinical benefit (reauth 1 year).

    Cosentyx initial coverage

    Cosentyx covered when ALL of the following are met:

    Cosentyx approval: Must not be used with other biologics, Otezla, or JAK inhibitors AND prescriber is a specialist or has consulted a specialist AND documentation of prior therapies and responses provided including indication‑specific prior trials (e.g., NSAID for AS; traditional immunomodulator for psoriasis)

    Coverage duration two years; dosing per FDA label or compendia.

    Dalfampridine safety criteria

    Dalfampridine ER safety criteria — covered when ALL of the following are met:

    Dalfampridine approval: No history of seizure AND creatinine clearance >50 mL/min AND baseline timed 25‑foot walk demonstrating ambulatory statusCrCl > 50 mL/min

    Initial and reauthorization coverage 1 year; reauth requires stability or improvement in walking speed.

    Dupixent initial and reauthorization criteria

    Dupixent coverage when the applicable indication-specific criteria are met:

    Asthma initial coverage: Oral corticosteroid‑dependent asthma OR eosinophilic phenotype (blood eosinophils ≥150 cells/µL at initiation or ≥300 cells/µL in past 12 months) AND trial and failure of 1 ICS/LABA in past 6 monthsblood eosinophils >=150 cells/µL at initiation or >=300 cells/µL in prior 12 months

    Initial approval 1 year; reauth 2 years; reauthorization requires clinical benefit vs baseline.

    EoE initial coverage: Esophageal biopsy with ≥15 eosinophils per HPF AND weight ≥15 kg AND symptoms of esophageal dysfunction AND trial and failure of PPI or swallowed topical steroid for ≥2 months>=15 eosinophils/HPF

    Reauthorization requires reduced eosinophil count or symptom improvement.

    Chronic urticaria initial coverage: Urticaria >6 weeks AND trial and failure of one H1 antihistamine

    Ebglyss AD criteria

    Ebglyss (atopic dermatitis) coverage when ALL of the following are met:

    Ebglyss initial coverage for AD: Confirmation of moderate to severe atopic dermatitis AND trial and failure of Rinvoq AND trial and failure of Dupixent

    Prescriber specialist required; initial limited to 4 doses first month then 2 doses/month thereafter; reauth 2 years with documentation of positive clinical response.

    Dupixent (chronic urticaria)

    Dupixent — chronic urticaria initial coverage when ALL of the following are met:

    Dupixent for chronic urticaria: Confirmed diagnosis of urticaria >6 weeks AND trial and failure of one H1 antihistamine>6 weeks

    Reauthorization requires documentation of clinical benefit vs baseline.

    Dupixent (bullous pemphigoid)

    Dupixent — bullous pemphigoid initial coverage when ALL of the following are met:

    Dupixent for bullous pemphigoid: Diagnosis of bullous pemphigoid AND trial and failure or intolerance to an oral or high‑potency topical steroid AND trial and failure of one steroid‑sparing agent (doxycycline, methotrexate, mycophenolate, or azathioprine)

    Reauthorization requires documentation of reduction in blister formation and itching.

    Eltrombopag (ITP)

    Eltrombopag — ITP initial coverage when ALL of the following are met:

    Eltrombopag for ITP: Platelet count <30,000/mcL OR <50,000/mcL with bleeding or bleeding risk factors AND inadequate response or intolerance to steroids or IVIG AND inadequate response or intolerance to rituximab or splenectomy AND not used in combination with other maintenance ITP agentsplatelet count <30,000/mcL OR <50,000/mcL with bleeding

    Reauthorization: platelet count <400 x10^9/L and documentation of positive response; use to normalize platelet counts is not covered.

    Emgality (migraine and cluster headache)

    Emgality coverage when indication-specific criteria are met:

    Emgality migraine prevention: At least four migraine days per month>= 4 migraine days/month

    Initial approval 1 year; reauth 2 years; reauthorization requires documentation of decreased migraine days per month; must not be used with another CGRP antagonist.

    Emgality cluster headache: Trial of verapamil with intolerance or inability to improve the condition

    Reauthorization requires documentation of decreased frequency or intensity of cluster headaches.

    Enbrel (rheumatologic indications)

    Enbrel coverage when the indication-specific criteria are met:

    Enbrel for RA: Trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate)

    Must not be used with other biologics, Otezla, or JAK inhibitors; prescriber specialist or consult required; coverage duration two years.

    Enbrel for ankylosing spondylitis: Trial and failure of one NSAID

    Dose must follow FDA labeling.

    Fasenra (asthma and EGPA)

    Fasenra — severe eosinophilic asthma and EGPA coverage when ALL of the following are met:

    Fasenra for severe eosinophilic asthma: Blood eosinophil count ≥150 cells/µL within 6 weeks OR ≥300 cells/µL in prior 12 months AND trial and failure of 1 ICS/LABA in past 6 months (≥4 weeks on therapy)blood eosinophils >=150 cells/µL within 6 weeks OR >=300 cells/µL in prior 12 months

    Prescriber specialist required; initial 1 year; reauthorization requires clinical benefit documentation.

    Fasenra for EGPA: Documentation patient has non‑severe EGPA (no life‑ or organ‑threatening manifestations)

    Reauthorization requires documentation of clinical benefit.

    Eohilia (eosinophilic esophagitis)

    Eohilia (EoE) coverage when ALL of the following are met:

    Eohilia for EoE: Esophageal biopsy with ≥15 eosinophils/HPF AND persistent symptoms despite ≥2 months PPI AND trial of topical corticosteroid (fluticasone or budesonide) for ≥2 months with continued symptoms>=15 eosinophils/HPF

    Age ≥11 years; prescriber specialist required (gastroenterologist or allergist); authorization limited to 12 weeks within a 1‑year authorization.

    Endari (sickle cell disease)

    Endari coverage when ALL of the following are met:

    Endari for sickle cell disease: Trial and failure of hydroxyurea (failure = continued pain episodes despite appropriate dosing or intolerance)

    Prescriber specialist recommended; coverage duration two years.

    Growth hormone products (pediatric and adult GHD)

    Growth hormone products — pediatric and adult criteria (high‑level):

    Pediatric GH initial criteria: Submit untreated growth velocity curve ≥1 year showing growth velocity <10th percentile for bone age and gender; open growth plates; bone age ≥1 year behind chronological age (exceptions apply); documented GH deficiency via two stimulation tests <10 ng/mL OR stimulation <15 ng/mL with low IGF‑1/IGFBP‑3see text

    Prescriber restriction: endocrinologist/gastroenterologist/nephrologist; coverage duration one year.

    Adult GHD confirmation: Confirm GHD by suboptimal response on appropriate GH‑stimulation test OR persistent childhood‑onset GHD OR documented pituitary/hypothalamic disease with ≥3 pituitary hormone deficiencies and low IGF‑1see text

    Prescriber restriction applies; coverage duration one year.

    Growth hormone (selected products)

    Selected growth hormone product highlights (same content summarized):

    Pediatric GH highlights: See pediatric GH initial criteria node for required growth velocity, bone age, stimulation testing, and exam findingssee text

    Coverage duration one year; specialist prescriber required.

    Biologic agents: combination exclusions and step requirements

    Biologic agents: combination exclusions and step therapy rules apply when ALL of the following are met:

    Combination exclusion: Must not be used in combination with other biologic drugs, Otezla, or JAK inhibitorsN/A

    Documentation of prior therapies and responses required; prescriber should be a specialist; indication‑specific prior trials required (e.g., RA: fail methotrexate; AS: fail NSAID; PsO: fail methotrexate).

    Prior therapy requirements by indication: RA: try and fail one traditional non‑biologic immunomodulator; AS: try and fail one NSAID; Psoriasis: try and fail one traditional non‑biologic immunomodulator; other indications: follow product‑specific step requirementssee text

    Exceptions for aggressive disease or concurrent initiation with certain DMARDs per product guidance.

    HAE products

    HAE product requirements — covered when ALL of the following are met:

    HAE diagnostic requirement: Submission of C4, C1‑INH protein, and C1‑INH function lab results confirming diagnosis

    Prescriber specialist (allergist/immunologist/hematologist) recommended; age limits apply per product; exclusions include concurrent ACE inhibitor use for certain agents.

    IVIG

    IVIG coverage considerations when ALL of the following are met:

    IVIG dosing and review: Provide current weight and requested dose AND dosing must follow FDA labeling or have documentation supporting requested dose AND weight‑adjust dose if BMI ≥30 or actual weight ≥20% above ideal AND medical records supporting diagnosis and doseBMI ≥30 or weight ≥20% above ideal triggers adjustment

    Acute myasthenic crisis with decompensation allowed; chronic routine use for stable MG not covered.

    Kalydeco

    Kalydeco coverage requirement:

    Ivacaftor (Kalydeco) requirement: Laboratory confirmation of an ivacaftor‑responsive CFTR mutation must be provided prior to coveragegenetic confirmation

    Coverage duration two years.

    Kerendia initial criteria

    Kerendia initial therapy requirements — covered when ALL of the following are met:

    Kerendia for HF (LVEF ≥40%): NYHA Class II–IV AND documented EF ≥40% within prior 12 months AND pre‑treatment eGFR ≥25 mL/min/1.73m2 AND prescribed by or in consultation with a cardiologist AND receiving at least two standard HF medications from different classes at appropriate doseseGFR >=25 mL/min/1.73m2; EF >=40%

    Coverage duration two years.

    Kerendia for CKD with T2DM: Trial of an SGLT2 inhibitor or GLP‑1 RA or documented rationale to add/switch AND on maximally tolerated ACEI or ARB AND eGFR ≥25 mL/min/1.73m2eGFR >=25 mL/min/1.73m2

    Coverage duration two years.

    Imatinib formulations

    Imatinib product‑specific notes — coverage when the following are met:

    Imatinib formulations: For imkeldi (non‑tablet) coverage requires inability to swallow or appropriately use generic imatinib tablet formulation; other imatinib products follow standard criteria with documentation as required

    Coverage duration as specified per product (commonly one to two years).

    Krazati — Covered with conditions

    Krazati coverage when ALL of the following are met:

    Krazati: Medical records must support use consistent with current NCCN recommendations

    Coverage duration two years.

    Levetiracetam ODT/soluble — Covered with prior therapy

    Levetiracetam ODT/soluble coverage when ALL of the following are met:

    Levetiracetam ODT/soluble: Documentation of inability to use generic levetiracetam tablet AND trial and failure with one other generic anticonvulsant

    Coverage duration two years; prior therapy required; requests may be denied without documentation.

    Livtencity — Covered with prior therapy and lab confirmation

    Livtencity coverage when ALL of the following are met:

    Livtencity: Baseline CMV DNA confirming diagnosis AND trial and failure with ganciclovir, valganciclovir, cidofovir or foscarnet AND not used concomitantly with other CMV antivirals

    Initial coverage eight weeks; reauthorization requires documented response (e.g., CMV DNA level).

    Nexletol / Nexlizet — Step therapy criteria

    Nexletol / Nexlizet — step therapy criteria (covered when ONE of the following is met):

    Nexletol / Nexlizet eligibility: Either: (1) Tried a high‑intensity statin (or maximally tolerated statin if high‑intensity not tolerated) PLUS ezetimibe ≥4 weeks with LDL‑C ≥70 mg/dL OR (2) Tried ezetimibe ≥4 weeks and statin‑intolerant defined as trial of ≥2 statins with statin‑related symptoms on bothLDL‑C >= 70 mg/dL

    Must submit most recent LDL‑C and prior therapy documentation; must not be used with PCSK9 inhibitors or Juxtapid; coverage duration two years.

    Nulibry — Genetic confirmation and response for reauth

    Nulibry coverage when ALL of the following are met:

    Nulibry: Confirmed diagnosis of molybdenum cofactor deficiency (MoCD) Type A by genetic testing; genetic test results must be submitted

    Initial 1 year; reauthorization 2 years with documentation of beneficial response in neurological/gross motor/developmental measures.

    Pulmonary arterial hypertension agents — diagnostic confirmation required

    Pulmonary arterial hypertension (PAH) agents — diagnostic confirmation required:

    PAH agents: Documentation that the patient has pulmonary arterial hypertension (WHO Group 1) confirmed by right heart catheterizationright heart catheterization confirming PAH

    Coverage duration two years where specified; prescriber specialist involvement recommended.

    Marplan — Step therapy requirement

    Marplan (antidepressant) step therapy requirement — covered when ALL are met:

    Marplan: Documentation of trial and failure with two generic antidepressants (SNRIs, SSRIs, mirtazapine, or bupropion)

    Coverage duration two years; prior therapy required.

    PAH product criteria

    PAH product criteria — covered when documentation and prerequisites are provided:

    PAH (WHO Group 1) products: Documentation that patient has pulmonary arterial hypertension (WHO Group 1) confirmed by right heart catheterizationright heart catheterization confirming PAH

    Coverage duration two years where specified; specialist prescriber recommended.

    Oxervate

    Oxervate coverage limits — covered when ALL of the following are met:

    Oxervate: Diagnosis of Stage 2 or 3 neurotrophic keratitis confirmed (e.g., slit lamp) AND prescribed by/with an ophthalmologistmaximum 8 weeks lifetime

    Dosing must follow FDA label; more than 8 weeks lifetime not covered.

    Pirfenidone (IPF)

    Pirfenidone (IPF) coverage when ALL of the following are met:

    Pirfenidone initial: High‑resolution CT (HRCT) confirming diagnosis; for IPF require surgical lung biopsy or UIP pattern on HRCT and exclusion of other known causes; prescriber is or has consulted with a pulmonologistHRCT or surgical biopsy consistent with IPF

    Coverage duration two years; reauthorization requires documentation of improvement.

    Radicava

    Radicava initial and reauthorization criteria — covered when ALL of the following are met:

    Radicava initial: Diagnosis of definite or probable ALS per revised El Escorial/Arlie House criteria AND diagnosis within 2 years AND baseline ALSFRS‑R item scores ≥2 (minimum total 24) AND % FVC ≥80%diagnosis ≤2 years; %FVC >=80%; ALSFRS‑R >=24

    Initial limited volumes (70 mL first 28 days; 50 mL every 28 days thereafter); reauthorization requires evidence Radicava is slowing progression.

    Redemplo (FCS)

    Redemplo (FCS) initial and reauthorization — covered when ALL of the following are met:

    Redemplo initial: Dosing aligns with FDA labeling AND confirmation of familial chylomicronemia syndrome (fasting triglycerides >880 mg/dL AND genetic testing or clinical diagnosis per guidance) AND prescribed by/with a specialist; age ≥18fasting TG >880 mg/dL

    Initial one year; reauthorization two years with documentation of benefit vs baseline.

    Revcovi

    Revcovi monitoring‑based coverage when ALL of the following are met:

    Revcovi: Provide trough plasma ADA activity and trough dAXP levels AND patient's current weight and requested dose; provider attestation that dosing will be adjusted to maintain trough ADA >30 mmol/hr/L and trough dAXP <0.02 mmol/L or adequate immune reconstitutiontrough ADA >30 mmol/hr/L and trough dAXP <0.02 mmol/L

    Initial and reauthorization one year.

    Repatha (PCSK9 inhibitor)

    Repatha (PCSK9 inhibitor) prior therapy requirements — covered when ONE of the following is met:

    Repatha prerequisites: Patient must meet one of: tried a high‑intensity statin and LDL‑C remains above goal; OR tried maximally tolerated statin and LDL‑C remains above goal; OR tried two different statins with statin‑related symptoms on bothstatin therapy history as specified

    Must submit prior therapy documentation; coverage duration two years.

    Biologic/JAKi agents

    Biologic/JAKi and other immunomodulator agents — coverage when ALL product‑specific criteria are met:

    Biologic/JAKi combination restriction: Must not be used in combination with other biologic drugs or JAK inhibitors for the same condition; documentation of prior therapies and responses required; prescriber should be a specialist or have consulted a specialistno concomitant biologic/JAKi per product

    Step therapy requirements vary by indication (e.g., methotrexate for RA, NSAID for AS); coverage durations commonly one to two years.

    General product coverage rule

    General product coverage rule — product covered when product‑specific conditions satisfied:

    Product‑level: Each product is covered when the specific documented requirements for that product (diagnostic confirmation, prior therapy trials, prescriber specialty, contraindication documentation) are satisfied as described in this section

    See individual product entries for details.

    Tavneos (avacopan) coverage criteria

    Tavneos (avacopan) coverage criteria — initial and reauthorization when ALL are met:

    Tavneos initial and reauth: Initial: age ≥18 AND documentation to support diagnosis AND prescribed by or in consultation with a specialist AND used as add‑on to standard therapy (cyclophosphamide, rituximab, steroids) AND patient not currently requiring dialysis; Reauthorization: reduction in BVAS and steroid dose must be demonstrated

    Initial 6 months; reauth 12 months.

    Sodium oxybate criteria

    Sodium oxybate (narcolepsy) criteria — covered when ALL of the following are met:

    Sodium oxybate initial coverage: Diagnosis confirmed by MSLT and polysomnography AND prescriber a sleep specialist or neurologist AND patient not receiving sedative hypnotics AND no succinic semialdehyde dehydrogenase deficiency AND prior trials failed: amphetamine salts/dextroamphetamine/methylphenidate AND either modafinil or armodafinil

    Coverage duration two years; reauthorization requires documentation of decreased excessive daytime sleepiness or cataplexy episodes.

    Rydapt coverage criteria

    Rydapt (midostaurin) AML coverage when ALL of the following are met:

    Rydapt for AML: FLT3 mutation‑positive disease documented by an FDA‑approved test AND used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy

    Age ≥18; coverage duration one year; mutation testing and combination therapy required.

    Secuado coverage criteria

    Secuado coverage criteria — covered when ALL of the following are met:

    Secuado prior therapy: Documentation of trial and failure with two listed generic antipsychotics for at least 28 days each (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone)28 days each

    Coverage duration two years.

    Tetrabenazine coverage criteria

    Tetrabenazine coverage criteria — covered when ALL of the following are met:

    Tetrabenazine dosing: Must not be used in combination with Austedo or Ingrezza; CYP2D6 genotype must be provided for doses >50 mg/dayCYP2D6 genotype for >50 mg/day

    Coverage duration two years.

    Teriparatide coverage criteria

    Teriparatide coverage criteria — covered when ONE of the following is met:

    Teriparatide: Either: (1) Trial and failure/intolerance/contraindication to alendronate, risedronate or ibandronate AND zoledronic acid; OR (2) very high fracture risk (T‑score ≤‑3.0 OR T‑score ≤‑2.5 with fragility fracture OR history of severe/multiple fragility fractures regardless of T‑score)T‑score criteria as specified

    Prescriber must be an endocrinologist; coverage duration two years.

    Testosterone coverage criteria

    Testosterone (transdermal) coverage when ALL of the following are met:

    Testosterone hypogonadism: Two pre‑treatment morning serum total testosterone levels on separate days <300 ng/dL AND pre‑treatment clinical signs/symptoms of low testosterone other than erectile dysfunction and decreased libido (e.g., depressed mood, decreased energy, progressive muscle loss, osteoporosis)two AM testosterone <300 ng/dL

    Coverage duration two years.

    Tofacitinib and related products

    Tofacitinib and related JAK inhibitor family coverage when ALL of the following are met:

    Tofacitinib / JAK inhibitor family: Must not be used in combination with other biologic drugs, Otezla, or other JAK inhibitors; documentation of prior therapies and responses required; prescriber should be a specialist or consult a specialist; for RA must have trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate); for AS must have trial/failure of one NSAID; for JIA prerequisites apply

    Coverage duration two years; specifics vary by indication.

    Products with combination exclusions and CYP2D6/genotype requirements

    Products with combination exclusions and CYP2D6/genotype requirements — covered when ALL product‑specific conditions are met:

    Combination exclusions & genotype: Products listed must not be used in specified combinations (e.g., Austedo/Ingrezza exclusions) AND where applicable CYP2D6 genotype must be provided for doses >50 mg/daydose >50 mg/day for genotype requirement

    Applies to specific products as noted in product entries.

    Tofacitinib (and similar agents) — rheumatologic requirements

    Tofacitinib (and similar agents) — rheumatologic requirements (covered when ALL are met):

    Tofacitinib RA/AS/JIA prerequisites: Not used with other biologics/Otezla/JAKis; documentation of prior therapies and responses required; prescriber specialist or consult required; for RA must fail one traditional non‑biologic immunomodulator; for AS must fail one NSAID; for JIA must fail one other drug or meet criteria for concurrent start

    Coverage duration two years.

    Tolvaptan — indication-specific criteria

    Tolvaptan — indication‑specific criteria (covered when relevant criteria are met):

    Hyponatremia pathway: Confirm hypervolemic or euvolemic hyponatremia with serum sodium <125 mEq/L OR symptomatic nonresponse to fluid restriction; dosing up to 60 mg/day per FDA labelingserum sodium <125 mEq/L

    Coverage duration hyponatremia: 30 days.

    ADPKD pathway: Patient at risk of rapidly progressing ADPKD AND dosing up to 120 mg/day per FDA labeling

    Coverage duration ADPKD: 2 years; prescriber documentation required.

    Tryngolza (Familial Chylomicronemia Syndrome)

    Tryngolza (FCS) initial and reauthorization criteria — covered when ALL are met:

    Tryngolza initial: Dosing aligns with FDA labeling AND prior trial of Redemplo with inadequate response or intolerance AND confirmation of FCS by fasting triglyceride >880 mg/dL AND exclusion of secondary causes AND genetic testing or clinical diagnosis per guidancefasting TG >880 mg/dL

    Initial one year; reauthorization two years with evidence of benefit vs baseline.

    Tryngolza reauth: Documentation of benefit vs baseline (e.g., biochemical response, fewer pancreatitis episodes) and dosing per FDA labeling

    Reauthorization requires documentation of clinical/biochemical benefit.

    Verquvo (heart failure)

    Verquvo (heart failure) coverage when ALL of the following are met:

    Verquvo initial criteria: Documentation of prior therapies and responses; EF <45% within 12 months; age ≥18; prescribed by or in consultation with a cardiologist; symptomatic worsening chronic heart failure (NYHA II–IV) with recent hospitalization or outpatient IV diuretics; trial or intolerance to maximally tolerated ACEI/ARB/ARNi plus beta‑blocker plus MRA/diureticEF <45%

    Coverage duration two years.

    Voydeya (PNH)

    Voydeya (PNH) coverage limited to adult PNH patients when ALL are met:

    Voydeya initial criteria: PNH confirmed by flow cytometry AND actively receiving ravulizumab or eculizumab AND symptomatic extravascular hemolysis defined as fatigue or dyspnea AND Hgb <9.5 g/dL OR ARC >120 x10^9/L AND age ≥18 AND not used with Fabhalta or EmpaveliHgb <9.5 g/dL OR ARC >120 x10^9/L

    Initial and reauthorization one year; reauth requires improved EVH symptoms and hematologic/transfusion benefit vs baseline.

    Voydeya reauthorization: Active treatment with Ultomiris/Soliris and documentation of improvement in EVH symptoms and sustained hematologic or transfusion benefit vs baseline

    Reauthorization one year.

    Vowst (recurrent C. difficile infection)

    Vowst (recurrent C. difficile infection) — single‑course coverage when ALL are met:

    Vowst initial: Documentation of at least 2 recurrent CDI episodes (3+ total) after failure of appropriate antibiotics AND age ≥1812 capsules over 3 days (one course)

    Limited to one treatment course; coverage duration one year.

    Vyndamax (ATTR-CM)

    Vyndamax (tafamidis) — initial coverage when ALL of the following are met:

    Vyndamax initial criteria: NYHA class I–III AND ECHO or CMR showing cardiac involvement (increased LV wall thickness) AND diagnosis confirmed by tissue biopsy, genetic testing, or radionuclide imaging (99mTc‑PYP/DPD/HMDP) AND if radionuclide imaging used document Grade 2 or 3 cardiac uptakeAge >=18

    Will not be approved for primary (light‑chain) amyloidosis; initial coverage one year; reauthorization requires documented clinical response vs baseline.

    Vigabatrin/vigadrone (refractory seizures)

    Vigabatrin/vigadrone coverage when ALL of the following are met:

    Vigabatrin/vigadrone initial criteria: Documentation of trial and failure with at least 2 other generic anticonvulsants for refractory complex partial seizures

    Prerequisite therapy required; prescriber documentation required.

    Ustekinumab (psoriasis and other indications)

    Ustekinumab coverage when ALL of the following are met:

    Ustekinumab criteria: Must not be used with other biologic drugs, Otezla, or JAK inhibitors; documentation of prior therapies and responses required; prescriber is or has consulted with a specialist; for psoriasis must try and fail one traditional non‑biologic immunomodulator

    Coverage duration two years.

    Vyndamax (ATTR-CM) — Initial Therapy

    Vyndamax — Initial Therapy (concise restatement):

    Vyndamax initial criteria (restated): NYHA class I–III AND imaging (ECHO/CMR) showing cardiac involvement AND diagnostic confirmation by biopsy, genetic testing, or radionuclide imaging with Grade 2–3 uptake if radionuclide modality used AND age ≥18

    Not approved for primary (light‑chain) amyloidosis; initial coverage one year.

    Vyndamax — Reauthorization

    Vyndamax — Reauthorization when ALL of the following are met:

    Vyndamax reauth criteria: Documentation of a positive clinical response to Vyndamax compared to baseline (examples: reduced cardiovascular‑related hospitalizations, improved function, improved quality of life)

    Reauthorization coverage duration one year.

    Documentation, Prescriber, and Prior Authorization Actions

    Prior Authorization

    Aimovig: document ≥4 migraine days/month; no concurrent CGRP therapy

    Initial Aimovig requests must document at least four migraine days per month and must not be used with another CGRP antagonist; reauthorization requires documentation of a decrease in migraine days per month. Initial approval is 1 year; reauthorization 2 years.

    Prior Authorization

    Amvuttra: submit mutation, PND, and indication-specific confirmation

    For Amvuttra initial requests provide diagnostic confirmation: TTR mutation, baseline PND ≤ IIIb and clinical signs for hATTR‑PN; for ATTR‑CM document prior failure/intolerance/contraindication to tafamidis, NYHA class I–III, ECHO/CMR showing cardiac involvement, and confirmatory biopsy, genetic testing, or radionuclide imaging (Grade 2–3 uptake if radionuclide used). Initial and reauthorization coverage durations are one year; reauth requires demonstration of clinical response versus baseline.

    Prior Authorization

    Drug/Product Index and Clinical Thresholds

    Products listed (drug names/strengths presented in text)mixed
    EBGLYSSEBGLYSS
    eltrombopag Olamine oral packet 12.5 mg, 25 mgeltrombopag olamine oral packet 12.5 mg, 25 mg
    eltrombopag Olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mgeltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg
    Products listedmixed
    OPSYNVIOPSYNVI
    ORENITRAMORENITRAM
    ORGOVYXORGOVYX
    ORKAMBI ORAL PACKETORKAMBI ORAL PACKET
    ORKAMBI ORAL TABLETORKAMBI ORAL TABLET
    XALKORI ORAL CAPSULEXALKORI ORAL CAPSULE
    VYNDAMAXVYNDAMAX
    No explicit CPT/HCPCS/ICD/NDC codes in this fragmentmixed
    No codes listed
    No explicit CPT/HCPCS/NDC codes in this segmentmixed
    No codes listed
    Indexed drugs (sample)mixed
    ALUNBRIG ORAL TABLET 180 MGALUNBRIG ORAL TABLET 180 MG
    BETASERON SUBCUTANEOUS KITBETASERON SUBCUTANEOUS KIT
    Indexed drugs (sample)mixed
    XALKORI ORAL CAPSULEXALKORI ORAL CAPSULE
    XELJANZ ORAL TABLETXELJANZ ORAL TABLET
    inv-120: Migraine frequency (clinical threshold)
    Migraine frequency (Aimovig/Emgality/Nurtec)>= 4 migraine days per month
    Nurtec episodic prevention range>=4 and <15 migraine days per month
    CGRP combination exclusionMust not be used with another CGRP antagonist therapy
    inv-121: Amvuttra age restriction
    Minimum age>= 18 years
    Amvuttra contraindication

    Initial Therapy: Medication-Specific Prerequisites

    Reauthorization and Continuation Requirements

    Step Therapy Requirements and Tables

    StepRequired prior trials / condition
    AUVELITY (depression)
    Must document trial and inadequate response after ≥4 weeks each of: one SSRI or SNRI AND one atypical antidepressant (e.g., bupropion, mirtazapine)
    StepRequired prior trials / condition
    Asenapine (Secuado / transdermal)
    Documentation of trial and inadequate response after at least 28 days each with two of the following generics: aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone
    StepRequired prior trials / condition
    Brivaracetam (oral)
    Must document trial and inadequate seizure control with generic levetiracetam AND at least one other generic anticonvulsant
    StepRequired prior trials / condition
    Cosentyx (secukinumab)
    Indication-specific: must document trial and inadequate response with required non-biologic therapies (e.g., NSAID for ankylosing spondylitis; one traditional non-biologic immunomodulator such as methotrexate, cyclosporine, or acitretin for psoriasis) before biologic approval
    StepRequired prior trials / condition
    Ebglyss (atopic dermatitis)
    Initial coverage requires documentation of trial and failure (inadequate response) with Rinvoq (upadacitinib) AND Dupixent (dupilumab) prior to approval
    StepRequired prior trials / condition
    Enbrel (etanercept; includes Enbrel Mini)
    For rheumatologic indications must document trial and failure (intolerance or inadequate response) of one traditional non-biologic immunomodulator (e.g., methotrexate); for ankylosing spondylitis must trial and fail one NSAID
    StepRequired prior trials / condition
    Endari (L-glutamine for sickle cell disease)
    Must document trial and failure or intolerance to hydroxyurea (continued pain episodes despite appropriate dosing or intolerance) before approval
    StepRequired prior trials / condition
    Conventional therapy try/fail (general immunologic biologics)
    For many biologic/JAK/ immunologic indications (RA, psoriasis, ankylosing spondylitis, HS, uveitis, JIA, etc.) must document trial and inadequate response or intolerance to one or more specified conventional non‑biologic therapies (examples: methotrexate, cyclosporine, acitretin, NSAID) prior to biologic or JAK initiation
    StepRequired prior trials / condition
    Imatinib (non-tablet formulations / imkeldi) step requirement
    Coverage of non-tablet imatinib formulation requires documentation patient is unable to swallow or appropriately use the generic imatinib tablet formulation
    StepRequired prior trials / condition
    Nexletol / Nexlizet (lipid-lowering agents)
    Patient must have tried a high-intensity statin (or maximally tolerated statin if high-intensity not tolerated) plus ezetimibe ≥4 weeks with LDL‑C ≥70 mg/dL OR tried ezetimibe ≥4 weeks and be statin‑intolerant (trial of ≥2 statins with symptoms); submit recent LDL‑C and prior therapy documentation
    StepRequired prior trials / condition
    Marplan (antidepressant) step requirement
    Documentation of trial and inadequate improvement with two generic antidepressants (from SNRIs, SSRIs, mirtazapine, or bupropion) required prior to coverage
    StepRequired prior trials / condition
    Psoriasis — step therapy (biologic/JAKi)
    For moderate‑to‑severe psoriasis must document trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) prior to biologic/JAKi; step not required for mild disease
    StepRequired prior trials / condition
    Rheumatoid arthritis — step therapy
    Must document trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) before coverage of specified agents (biologic or JAK)
    StepRequired prior trials / condition
    Perampanel (oral)
    Must have documentation of trial and inadequate seizure control with at least two generic anticonvulsants prior to approval
    StepRequired prior trials / condition
    Multi‑indication RA / AS / JIA step rules (e.g., tofacitinib / Xeljanz family)
    RA: trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate). AS: trial and failure of one NSAID. JIA: trial and failure of one other drug (e.g., methotrexate/sulfasalazine) or concurrent start with methotrexate/sulfasalazine/leflunomide or evidence of aggressive disease.
    StepRequired prior trials / condition
    Secuado (asenapine transdermal) antipsychotic trial requirement
    Requires documentation of trial and inadequate response with two listed generic antipsychotics (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone) used at least 28 days each prior to approval
    StepRequired prior trials / condition
    Tofacitinib (and similar JAK inhibitors) — multi‑indication step therapy
    Prior to JAK initiation: must document trial and failure of specified conventional therapies per indication (RA: methotrexate; AS: NSAID; JIA: other drug or concurrent DMARD) and not used in combination with other biologics, Otezla, or other JAK inhibitors
    StepRequired prior trials / condition
    Ustekinumab (psoriasis and other indications)
    Must document trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) prior to ustekinumab; must not be used with other biologics, Otezla, or JAK inhibitors
    StepRequired prior trials / condition
    Vraylar (cariprazine) antipsychotic trials
    Requires trial and inadequate response with two generic antipsychotics chosen from aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, or lurasidone (each used ≥28 days) prior to approval
    StepRequired prior trials / condition
    Required prior trials before biologic / JAK initiation (general)
    Documentation of trial and inadequate response to specified conventional therapies per indication (examples: methotrexate for RA; NSAID for ankylosing spondylitis) is required before initiating many biologic or JAK agents; prescriber should be specialist or have consulted specialist
    StepRequired prior trials / condition
    Required prior trials (misc) — lipid and antidepressant examples
    Lipid agents (Nexletol/Nexlizet): high-intensity statin + ezetimibe ≥4 weeks or ezetimibe ≥4 weeks with documented statin intolerance; Antidepressants (Marplan/AUVELITY contexts): trial and failure with two generics prior to coverage as specified

    Quantity Limits and Dosing Restrictions

    inv-343: ACTHAR quantity limits
    ACTHAR quantity limitDosage limited to that supported by FDA label
    Coverage durationInitial coverage 6 weeks; reauthorization requires demonstrated clinical benefit
    Prerequisite trialsTherapeutic trial of parenteral glucocorticoid AND Cortrophin required for covered indications (except infantile spasms)
    inv-344: Ebglyss dosing limits
    Ebglyss initial dosing limitInitial limited to 4 doses first month and 2 doses each month thereafter
    Maintenance dosingMaintenance: every 4 weeks; may use every 2 weeks if inadequate response

    Prescriber and Site-of-Care Requirements

    Note

    Arikayce: specialist prescriber or consult required

    Arikayce must be prescribed by or in consultation with an infectious disease specialist or pulmonologist (site‑of‑care requirement).

    Note

    Colistimethate: IV/IM only, ID specialist consult and infection documentation required

    Colistimethate is covered only for IV or IM administration; nebulization/inhalation is not covered and an infectious disease specialist must prescribe or be consulted; provide culture/susceptibility or local epidemiology to support use.

    Billing Rule

    Part B vs Part D: submit diagnosis and administration info to determine benefit

    Policy Purpose and Scope

    This document sets Priority Health’s Medicare prior authorization requirements for pharmacy and specialty drugs. It is intended to guide clinical and billing staff on the coverage conditions that must be met before authorization is issued, including required diagnostic confirmation, specified prior therapy trials or failures, prescriber specialty or consultation, dosing/quantity limits aligned with FDA labeling, and reauthorization evidence of clinical benefit.

    Coverage rules are drug- and indication-specific and are organized alphabetically by product. Typical controls include step-therapy requirements (trial and failure of one or more conventional therapies), combination exclusions (e.g., no concomitant use of other biologics, Otezla, or JAK inhibitors where stated), laboratory or genetic test confirmation when required, and site-of-care or prescriber specialist requirements for selected agents.

    Authorization durations and utilization limits vary by product; common patterns are initial approvals of 1 year with reauthorizations of 2 years for many specialty drugs, shorter initial courses when clinically appropriate (examples: 6 months for Arikayce; Oxervate limited to 8 weeks lifetime), and quantity limits that follow FDA labeling or product-specific caps. Supporting medical records must document prior therapies, responses, and the specific clinical data called for in each drug’s criteria.

    Clinical Definitions and Diagnostic Criteria

    inv-280: Failure/Trial definition
    Definition of failure/trialFailure commonly defined as intolerance or inability to improve symptoms despite therapy; documentation required
    Specification for step therapyMany agents require trial and failure of specified prior therapies before approval
    DocumentationMedical records must show prior therapy trials and responses
    inv-281: ATTR-CM confirmation
    ATTR‑CM confirmation methodsDiagnosis confirmation may include tissue biopsy, genetic testing, or radionuclide imaging with Grade 2–3 uptake when radionuclide used
    Imaging requirementsECHO or CMR demonstrating cardiac involvement (increased LV wall thickness) required
    Policy Summary
    Payerpriority health
    PolicyMedicare prior authorization criteria — pharmacy & specialty drugs
    Policy CodePolicy 26328
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit required prior-therapy documentation and diagnosis confirmation per product-specific criteria when requesting prior authorization.
    SourceLink
    On This Page
    Per-Product Coverage Criteria (Alphabetical Index)Documentation, Prescriber, and Prior Authorization ActionsDrug/Product Index and Clinical ThresholdsInitial Therapy: Medication-Specific PrerequisitesReauthorization and Continuation RequirementsStep Therapy Requirements and TablesQuantity Limits and Dosing RestrictionsPrescriber and Site-of-Care RequirementsPolicy Purpose and ScopeClinical Definitions and Diagnostic Criteria
    >6 weeks

    Reauthorization requires documented clinical benefit vs baseline.

    Arikayce: sputum culture + specialist prescriber required

    Arikayce initial requests must include a sputum culture confirming MAC lung disease, documentation of failure to obtain negative cultures after ≥6 months of an appropriate multidrug regimen, and the drug must be prescribed by or in consultation with an infectious disease specialist or pulmonologist. Initial approval is 6 months; reauthorization 12 months and requires a negative sputum culture within the last 30 days and clinical response documentation.

    Prior Authorization

    ACTHAR: provide prior-therapy documentation and limit to FDA dosing

    ACTHAR requests must include documentation of prior therapies and responses; dosing and quantity are limited to FDA‑supported dosing. Initial coverage duration is 6 weeks; reauthorization requires demonstrated clinical benefit. Note exclusions for acute gouty arthritis, severe psoriasis, and atopic dermatitis.

    Documentation Required

    BRAFTOVI: document BRAF V600 mutation

    BRAFTOVI coverage requires submitted documentation of BRAF V600 mutation status prior to approval.

    Documentation Required

    BRUKINSA: provide rationale if substituting for Calquence/Imbruvica

    When requesting BRUKINSA for certain hematologic malignancies, the prescriber must provide rationale explaining why alternative agents (Calquence or Imbruvica) cannot be used in place of BRUKINSA.

    Prior Authorization

    Colistimethate: ID specialist plus culture/susceptibility required; no nebulization

    Prescribe colistimethate IV or IM only and ensure an infectious disease specialist prescribes or is consulted; submit culture and susceptibility data or local epidemiology demonstrating the organism is susceptible. Nebulized/inhalation administration is not covered.

    Prior Authorization

    CORTROPHIN: meet FDA duration and submit indication‑specific prior trials

    CORTROPHIN initial requests must follow FDA labeling (or max 3 months if unspecified) and include indication‑specific prerequisite trials (e.g., parenteral plus oral glucocorticoid for MS exacerbations); infantile spasms are exempt. Reauthorization requires demonstrated clinical benefit and quantity limited to FDA‑supported dosing.

    Prior Authorization

    Cosentyx: no concomitant biologics/JAKi; document indication‑specific prior trials

    Cosentyx must not be used in combination with other biologics, Otezla, or JAK inhibitors. Providers must document prior therapy trials specific to the indication (e.g., NSAID for ankylosing spondylitis; traditional immunomodulator for psoriasis) and be a specialist or consult one.

    Documentation Required

    Dalfampridine ER: exclude seizure history, CrCl >50 mL/min, baseline T25FW

    Dalfampridine ER requests must confirm no history of seizure, creatinine clearance >50 mL/min, and provide a baseline timed 25‑foot walk demonstrating ambulatory status; reauthorization requires stability or improvement in walking speed. Initial and reauthorization coverage are 1 year.

    Documentation Required

    Duloxetine alternative: document inability to use duloxetine + trial/failure of another generic

    For duloxetine alternatives (e.g., Drizalma), submit documentation that the patient is unable to use duloxetine and has trialed and failed one other generic antidepressant.

    Prior Authorization

    Ebglyss: failed Rinvoq and Dupixent, specialist prescriber, maintenance dosing limits

    Ebglyss initial coverage for atopic dermatitis requires documentation of moderate‑to‑severe disease, trial and failure of Rinvoq and Dupixent, and specialist prescriber involvement; initial dosing limited to 4 doses first month then 2 doses monthly, and reauthorization requires documented positive clinical response versus baseline.

    Documentation Required

    Dupixent: provide diagnosis confirmation and prior‑therapy documentation

    Submit indication‑specific documentation for Dupixent (diagnosis confirmation and required prior therapy trials). For chronic urticaria initial requests, document urticaria >6 weeks and trial/failure of one H1 antihistamine; reauthorization requires clinical benefit versus baseline.

    Prior Authorization

    Eltrombopag: platelet thresholds plus prior therapy trials and no concurrent TPO‑R agents

    Eltrombopag prior authorization requires current platelet count meeting thresholds (<30,000/mcL or <50,000/mcL with bleeding/risk), documentation of inadequate response or intolerance to steroids/IVIG and to rituximab or splenectomy, and it must not be combined with other maintenance thrombopoietic agents; reauth requires platelet <400 x10^9/L and evidence of response.

    Prior Authorization

    Emgality: ≥4 migraine days/month (migraine) or verapamil trial (cluster); no concurrent CGRP therapy

    Emgality for migraine prevention requires at least four migraine days per month; for cluster headache, document trial of verapamil with intolerance or failure. Emgality must not be used with another CGRP antagonist. Reauthorization requires documentation of decreased frequency/intensity.

    Prior Authorization

    Enbrel: document required prior non‑biologic trials; no concomitant biologics/JAKi

    Enbrel prior authorization requires documentation of prior therapies and trial/failure of specified non‑biologic agents per indication (e.g., methotrexate for RA; NSAID for ankylosing spondylitis). Enbrel must not be used with other biologics, Otezla, or JAK inhibitors; prescriber should be a specialist or consult one.

    Documentation Required

    Fasenra: submit eosinophil counts and failed ICS/LABA; specialist involvement required

    Fasenra requests must include blood eosinophil counts (≥150 cells/µL within 6 weeks or ≥300 cells/µL in prior 12 months), documentation of trial and failure of an ICS/LABA in the past 6 months, and specialist involvement; reauthorization requires documentation of clinical benefit.

    Prior Authorization

    Many specialty drugs: prior authorization per product‑specific criteria

    The listed specialty products require prior authorization per their product‑specific criteria; providers must supply the specified documentation, prescriber specialty (when required), and meet the stated coverage durations.

    Documentation Required

    Kalydeco: genetic test confirming ivacaftor‑responsive CFTR mutation required

    Kalydeco coverage requires laboratory confirmation of an ivacaftor‑responsive CFTR mutation prior to approval.

    Documentation Required

    Krazati: submit records showing NCCN‑aligned use

    Krazati prior authorization requires medical records demonstrating use follows current NCCN recommendations; coverage duration is two years.

    Documentation Required

    Levetiracetam ODT/soluble: document inability to use generic tablet + trial/failure

    Levetiracetam ODT/soluble requests must include documentation of inability to use generic levetiracetam tablet and trial/failure with one other generic anticonvulsant; absence of this documentation may result in denial.

    Prior Authorization

    Livtencity: baseline CMV DNA and prior antiviral trial/failure required; no concomitant CMV antivirals

    Livtencity prior authorization requires baseline CMV DNA confirming diagnosis, documentation of trial and failure with ganciclovir/valganciclovir/cidofovir or foscarnet, and it must not be used concomitantly with other CMV antivirals; reauthorization requires evidence of response (e.g., CMV DNA level).

    Prior Authorization

    Nexletol/Nexlizet: recent LDL‑C and statin/ezetimibe step documentation; no PCSK9/Juxtapid

    Nexletol and Nexlizet require submission of the most recent LDL‑C and documentation of prior statin/ezetimibe therapy and response: either high‑intensity statin plus ezetimibe ≥4 weeks with LDL‑C ≥70 mg/dL, or ezetimibe ≥4 weeks with statin intolerance (≥2 statin trials with symptoms). Do not use concomitantly with PCSK9 inhibitors or Juxtapid.

    Prior Authorization

    Orgovyx: document trial/failure with Firmagon (degarelix)

    Orgovyx prior authorization requires documentation of trial and failure with Firmagon (degarelix) before coverage; prerequisite therapy must be documented.

    Prior Authorization

    Prior authorization required for listed specialty drugs

    Prior authorization is required for many listed specialty drugs; providers must submit indication‑specific documentation, prior therapy trials, prescriber specialty evidence (when required), and meet product durations (commonly two years unless noted).

    Documentation Required

    Radicava: baseline ALS criteria (%FVC, ALSFRS‑R) and reauth evidence of slowed progression

    Radicava prior authorization requires ALS diagnosis per revised El Escorial/Arlie House criteria (definite or probable), diagnosis ≤2 years, baseline ALSFRS‑R item scores ≥2 (total ≥24), %FVC ≥80%, and dosing within specified volume limits; reauthorization requires documentation that Radicava is slowing progression.

    Prior Authorization

    Per‑product prior authorization: follow each product's documented requirements

    All products in the list require prior authorization per their specific entries; providers must follow the product‑level criteria for documentation, prescriber specialty, and coverage duration as specified.

    Prior Authorization

    Tofacitinib: prior auth and indication‑specific prior therapy documentation required

    Tofacitinib entries require prior authorization and documentation of prerequisite therapies per indication (e.g., RA: trial and failure of one traditional non‑biologic immunomodulator; AS: trial and failure of one NSAID; JIA: specified prerequisites). Providers should document specialist involvement.

    Prior Authorization

    Vowst: document recurrent CDI after antibiotic failures; one 12‑capsule course only

    Vowst prior authorization requires documentation of at least two recurrent CDI episodes (three or more total) after failure of appropriate antibiotics; limited to one treatment course (12 capsules over 3 days); initial coverage duration one year.

    Prior Authorization

    Tolvaptan: submit indication‑specific labs and limit dosing to FDA‑labeled maxima

    Tolvaptan prior authorization requires indication‑specific documentation: for hyponatremia confirm hypervolemic/euvolemic hyponatremia with serum sodium <125 mEq/L or symptomatic nonresponse to fluid restriction (dosing up to 60 mg/day); for ADPKD document risk of rapid progression (dosing up to 120 mg/day). Coverage durations vary by indication.

    Prior Authorization

    Voydeya: PNH confirmation, active complement inhibitor therapy, and EVH criteria required

    Voydeya prior authorization requires PNH diagnosis by flow cytometry, active treatment with ravulizumab or eculizumab, and evidence of symptomatic extravascular hemolysis (fatigue or dyspnea plus Hgb <9.5 g/dL or ARC >120 x10^9/L). Initial and reauthorization coverage are one year.

    Prior Authorization

    Tryngolza: FCS confirmation (TG>880 mg/dL) and prior Redemplo trial required

    Tryngolza prior authorization requires confirmation of familial chylomicronemia syndrome (fasting triglycerides >880 mg/dL and exclusion of secondary causes with genetic testing or clinical diagnosis) and documentation of prior Redemplo trial with inadequate response or intolerance; initial coverage one year, reauthorization two years with evidence of benefit.

    Prior Authorization

    Vyndamax: multi‑modality ATTR‑CM confirmation; exclude primary (light‑chain) amyloidosis

    Vyndamax (tafamidis) initial and reauthorization require NYHA class I–III, ECHO or CMR demonstrating cardiac involvement, and diagnosis confirmation by biopsy, genetic testing, or radionuclide imaging (Grade 2–3 uptake if radionuclide used); Vyndamax will not be approved for primary (light‑chain) amyloidosis. Reauthorization requires documentation of positive clinical response versus baseline.

    Prior Authorization

    Xolair: indication‑specific documentation (IgE, allergen testing, weight) for PA

    Xolair prior authorization is required for asthma, food allergy, chronic urticaria, and nasal polyps; submit indication‑specific documentation (e.g., baseline IgE ≥30 IU/mL and positive perennial aeroallergen test for asthma, current weight, trial/failure of an ICS/LABA within 6 months) and evidence of benefit on reauthorization.

    Prior Authorization

    Xifaxan: follow indication limits (IBS‑D ≤3 courses; TD ≤3 days); SIBO not covered

    Xifaxan prior authorization requires adherence to indication‑specific limits and prerequisites: IBS‑D limited to no more than three 14‑day courses; traveler’s diarrhea limited to three days with prior azithromycin trial/failure; SIBO coverage is not provided.

    Denial Risk

    Biologics: do not combine with other biologics, Otezla, or JAK inhibitors

    Use of other biologic drugs, Otezla, or JAK inhibitors in combination with specified biologics will trigger exclusion/denial; providers must not request combination biologic/JAKi therapy for these products.

    Step Therapy

    Depression agents: SSRI/SNRI + one atypical antidepressant trial required

    For certain depression agents (e.g., AUVELITY) try and fail an SSRI or SNRI and one atypical antidepressant (e.g., bupropion or mirtazapine) before approval; document trials and outcomes.

    Step Therapy

    Asenapine/Secuado: two generic antipsychotic trials (≥28 days each) required

    Asenapine (Secuado) requires documented trial and failure with two specified generic antipsychotics for at least 28 days each prior to coverage.

    Step Therapy

    Brivaracetam: prior levetiracetam + another generic anticonvulsant trial required

    Brivaracetam (oral) requires documentation of trial and failure with generic levetiracetam plus at least one other generic anticonvulsant (failure defined as inadequate seizure control) before approval.

    Step Therapy

    Calcipotriene‑betamethasone (scalp): trial of generic steroid + calcipotriene required

    For calcipotriene‑betamethasone suspension (scalp), document trial and failure of a generic topical steroid (e.g., fluocinonide or clobetasol solution) plus generic calcipotriene solution prior to approval.

    Step Therapy

    Caplyta: document required prior antipsychotic trials per indication

    Caplyta requests must include documentation of prior therapies and required indication‑specific antipsychotic trial/failure patterns (e.g., two generic atypical antipsychotics for schizophrenia).

    Step Therapy

    Cosentyx: indication‑specific non‑biologic trials required before biologic

    Cosentyx requires prior non‑biologic therapy trials per indication (e.g., NSAID for ankylosing spondylitis; traditional immunomodulator for psoriasis) before biologic initiation; providers must document trials and responses.

    Step Therapy

    Ebglyss: must have failed Rinvoq and Dupixent

    Ebglyss initial therapy requires prior failure of Rinvoq and Dupixent for atopic dermatitis before approval.

    Step Therapy

    Enbrel: trial/failure of traditional non‑biologic therapy (e.g., methotrexate) required

    Enbrel (and Enbrel Mini) requires trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate) for RA and psoriasis prior to approval; for ankylosing spondylitis a trial and failure of one NSAID is required.

    Step Therapy

    Endari: trial and failure of hydroxyurea required

    Endari prior authorization requires documentation that the patient tried and failed hydroxyurea (continued pain episodes despite appropriate dosing or intolerance) before approval.

    Step Therapy

    Biologics/JAKi: document trial/failure of conventional therapies per indication

    Many biologic/JAKi indications require trial and failure of one or more specified conventional therapies (examples include methotrexate, NSAIDs, cyclosporine); providers must document prior trials unless exceptions apply.

    Step Therapy

    Nexletol/Nexlizet: statin+ezetimibe or ezetimibe with statin‑intolerance evidence required

    Nexletol/Nexlizet step requirement: patient must have tried a high‑intensity statin (or maximally‑tolerated statin) plus ezetimibe for ≥4 weeks with LDL‑C ≥70 mg/dL OR ezetimibe ≥4 weeks with statin intolerance (trial of ≥2 statins with symptoms); submit recent LDL‑C and prior therapy documentation.

    Step Therapy

    Antidepressant step: two generic antidepressant trials required

    For certain antidepressant approvals (e.g., Marplan) providers must document trial and failure with two generic antidepressants (SNRIs, SSRIs, mirtazapine, or bupropion).

    Step Therapy

    Livtencity: prior CMV antiviral trial + baseline CMV DNA required

    Livtencity requires trial and failure with ganciclovir, valganciclovir, cidofovir, or foscarnet prior to approval; baseline CMV DNA must be submitted and reauthorization requires documented response.

    Step Therapy

    Psoriasis: try and fail one traditional non‑biologic immunomodulator before biologic

    For moderate to severe psoriasis agents (examples Yesintek, ustekinumab), providers must document trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate, cyclosporine, acitretin) before biologic/JAKi coverage.

    Step Therapy

    RA/axial spondyloarthritis: document required prior non‑biologic trials (e.g., methotrexate, NSAID)

    Rheumatoid arthritis and axial spondyloarthritis prior authorization/step requirements: providers must document trial and failure of one traditional non‑biologic immunomodulator (e.g., methotrexate) for RA and one NSAID for axial spondyloarthritis before coverage of specified agents.

    Documentation Required

    Prior therapy documentation: submit records showing trial/failure or intolerance

    For many products, providers must submit supporting documentation of prior drug trials and responses demonstrating inadequate response, intolerance, or FDA‑labeled contraindication; missing prior‑therapy documentation can trigger denial.

    Documentation Required

    Amvuttra: submit mutation test, baseline PND, and confirmatory diagnostics

    For Amvuttra provide mutation testing, baseline PND score, clinical signs, and confirmatory diagnostics (biopsy, genetic testing, or radionuclide imaging); for ATTR‑CM include NYHA class and imaging showing cardiac involvement.

    Documentation Required

    Arikayce: provide initial and reauth sputum culture documentation

    Arikayce initial review requires submission of a sputum culture confirming MAC and documentation of failure to obtain negative cultures after ≥6 months of a multidrug background regimen; reauthorization requires a negative sputum culture within 30 days and clinical response documentation.

    Documentation Required

    Nexletol/Nexlizet: submit recent LDL‑C and prior therapy records or risk denial

    Nexletol/Nexlizet documentation must include the most recent LDL‑C and records of prior statin/ezetimibe therapy and response; lack of recent LDL‑C or prior‑therapy documentation may result in denial.

    Documentation Required

    Redemplo: fasting TG >880 mg/dL + genetic or clinical confirmation required

    Redemplo initial requests must include fasting triglyceride >880 mg/dL (10 mmol/L) and genetic testing or clinical diagnosis per guidance; dosing must align with FDA labeling and prescriber should be a specialist.

    Documentation Required

    Vowst: document ≥2 recurrences after antibiotics; one 12‑capsule course only

    For Vowst, submit documentation of at least two recurrent CDI episodes (three or more total) after failure of appropriate antibiotics; limited to one treatment course (12 capsules over 3 days).

    Documentation Required

    Vyndamax: submit NYHA, imaging, and diagnostic confirmation; exclude primary amyloidosis

    Vyndamax initial documentation requires NYHA class I–III, ECHO or CMR showing cardiac involvement, and diagnosis confirmation by biopsy, genetic testing, or radionuclide imaging (Grade 2–3 uptake if radionuclide used); Vyndamax will not be approved for primary (light‑chain) amyloidosis.

    Documentation Required

    Xifaxan: follow course limits (IBS‑D ≤3×14 days; TD ≤3 days); SIBO not covered

    Xifaxan for IBS‑D is limited to up to three 14‑day courses; traveler’s diarrhea limited to three days (requires azithromycin trial/failure); coverage for SIBO is not provided.

    Denial Risk

    Combination biologic/JAKi exclusion: do not request concurrent biologic/JAKi therapy

    Biologic products must not be used in combination with other biologic drugs, Otezla, or JAK inhibitors for the same condition; requests that propose such combinations will be denied.

    Denial Risk

    CGRP agents: no concurrent CGRP antagonist therapy; meet indication thresholds

    CGRP antagonists (Aimovig, Emgality) must not be combined with another CGRP antagonist; providers must document single‑agent use and meet migraine frequency or other indication‑specific prerequisites.

    Denial Risk

    Colistimethate: inhalation not supported — IV/IM only with culture/susceptibility

    Colistimethate requests for inhalation/nebulization will not be supported; IV or IM administration only and must include culture/susceptibility or local epidemiology showing likely susceptibility to justify use.

    Denial Risk

    PAH agents: right heart cath confirmation required or risk denial

    When requesting PAH agents providers must submit documentation confirming pulmonary arterial hypertension (WHO Group 1) by right heart catheterization; absence of right heart catheterization documentation may lead to denial.

    Denial Risk

    Oxervate: lifetime limit 8 weeks and ophthalmologist prescriber required

    Oxervate requests exceeding an 8‑week lifetime treatment will not be covered; initial approval requires documentation of Stage 2 or 3 neurotrophic keratitis and ophthalmologist prescriber or consultation.

    Denial Risk

    Sodium oxybate: MSLT/PSG required; no sedative hypnotics or SSADH deficiency

    For sodium oxybate, do not prescribe with concurrent sedative hypnotics or in patients with succinic semialdehyde dehydrogenase deficiency; provide MSLT and polysomnography documentation confirming narcolepsy.

    Denial Risk

    Vyndamax denial risk: exclude primary (light‑chain) amyloidosis

    Vyndamax will not be approved if the patient has primary (light‑chain) amyloidosis; providers must confirm ATTR‑CM diagnostic pathway and exclude primary amyloidosis.

    Note

    Index: follow referenced product entry for exact prior‑auth rules

    Index entries point to the main policy locations for detailed prior authorization rules; use the referenced product entry in the policy for exact documentation and prior‑therapy requirements.

    Documentation Required

    HAE: submit C4 and C1‑INH labs; ACEI co‑use not covered for icatibant/SAJAZIR

    HAE treatments require submission of C4, C1‑INH protein, and C1‑INH function lab results confirming diagnosis; concurrent ACE inhibitor use is not covered for icatibant/SAJAZIR.

    Documentation Required

    IVIG: submit weight, dose rationale, and records; adjust dose if BMI≥30 or weight ≥20% over ideal

    IVIG requests must include current weight and requested dose, documentation that dosing follows FDA labeling or accepted practice, and weight‑adjusted dosing if BMI ≥30 or actual weight ≥20% above ideal; provide supporting medical records for diagnosis and dose.

    Documentation Required

    Nulibry: genetic confirmation of MoCD Type A required

    Nulibry requests require confirmed genetic testing demonstrating MoCD Type A; lack of genetic confirmation may result in denial and reauthorization requires evidence of neurologic/functional benefit.

    Note

    PAH/Winrevair: specialist prescriber + right heart cath and prior therapy documentation

    For PAH, specialty agents and Winrevair must be prescribed by or in consultation with a specialist and include right heart catheterization documentation and prior therapy history (e.g., failure of dual PDE inhibitor + endothelin receptor antagonist where required).

    Note
    Note
    Note
    Note
    Not approved if patient has primary (light‑chain) amyloidosis
    Coverage durationInitial and reauthorization: 1 year
    inv-122: Benlysta SELENA-SLEDAI
    SELENA‑SLEDAI threshold>= 6
    Serology requirementAnti‑dsDNA >30 IU/mL OR ANA >1:80 for SLE initial requests
    Concomitant therapy requirementPatient taking two of: steroid, immunosuppressant, and/or hydroxychloroquine for >=12 weeks
    inv-123: Dupixent eosinophil threshold
    Dupixent eosinophil threshold (asthma)>=150 cells/µL at initiation OR >=300 cells/µL in past 12 months
    Blood eosinophil timingMeasurement within 6 weeks prior to therapy initiation accepted
    Required prior therapy (asthma)Trial and failure of one ICS/LABA in past 6 months
    inv-124: CORTROPHIN reauthorization/initial duration
    Initial durationInitial use per FDA label or maximum 3 months if unspecified
    Reauthorization intervalReauthorization: 1 year
    Prerequisite trialsIndication‑specific prior trials required (e.g., parenteral + oral glucocorticoid for MS exacerbation)
    inv-125: Dalfampridine renal function
    Renal function requirementCreatinine clearance >50 mL/min
    Seizure history exclusionNo history of seizure (contraindication)
    Baseline functional measureBaseline timed 25‑foot walk demonstrating ambulatory status required
    inv-126: Dupixent for EoE biopsy threshold
    EoE histologic threshold (Dupixent)>=15 eosinophils per high power field (HPF) on esophageal biopsy
    Age/weight requirementPatient weight >=15 kg and age per product labeling (EOE node: age >=11 for some entries)
    Prior therapy requirementPersistent symptoms after >=2 months PPI and trial of topical corticosteroid >=2 months
    inv-127: Blood eosinophil count
    Blood eosinophil count for biologics>=150 cells/µL within 6 weeks OR >=300 cells/µL in previous 12 months
    Use for Fasenra/DupixentCounts support severe eosinophilic asthma or eosinophilic phenotype for therapy initiation
    Documentation timingRecent lab within specified window (e.g., 6 weeks) required for initial review
    inv-128: ITP platelet count
    ITP platelet thresholds<30,000/mcL OR <50,000/mcL with bleeding or bleeding risk factors
    Prior therapy requirementsInadequate response or intolerance to steroids/IVIG AND to rituximab or splenectomy required
    ExclusionNot to be used with other maintenance ITP agents (e.g., other TPO‑R agonists)
    inv-129: Chronic urticaria duration
    Chronic urticaria duration> 6 weeks
    Prior therapy requirementTrial and failure of one H1 antihistamine required for initial coverage
    Reauthorization requirementDocumentation of clinical benefit compared to baseline
    inv-130: EoE biopsy eosinophils
    EoE biopsy eosinophil threshold>= 15 eosinophils per high power field (HPF)
    Symptom and prior therapy criteriaPersistent symptoms after >=2 months PPI and trial of topical steroid >=2 months
    Age restrictionEsophageal biopsy criteria applied for age >=11 in policy entry
    inv-131: LDL-C threshold
    LDL‑C threshold for Nexletol/Nexlizet>= 70 mg/dL
    Required prior therapyTrial of high‑intensity statin + ezetimibe >=4 weeks OR ezetimibe >=4 weeks with statin intolerance
    Combination exclusionMust not be used with PCSK9 inhibitors (e.g., Repatha) or Juxtapid
    inv-132: Migraine days per month (Nurtec episodic prevention)
    Nurtec (episodic prevention) migraine frequency>=4 and <15 migraine days per month
    Aimovig/Emgality overlapSame >=4 migraine days/month threshold used for Aimovig and Emgality prevention entries
    Reauthorization evidenceDocumentation of decreased migraine days per month required for reauthorization
    inv-133: AAT level and FEV1
    AAT level and FEV1 criteria (Prolastin‑C)FEV1 <80% predicted AND serum AAT <11 micromoles/L (or 80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry)
    Indication contextApplies to augmentation therapy for alpha‑1 antitrypsin deficiency per product entry
    DocumentationObjective pulmonary function and lab confirmation required
    inv-134: Radicava functional and respiratory thresholds
    Radicava respiratory/functional thresholds%FVC >= 80% predicted AND baseline ALSFRS‑R item scores >=2 (minimum total >=24)
    Diagnosis timingALS diagnosis must be <=2 years for initial Radicava requests
    Reauthorization evidenceDocumentation that Radicava is slowing progression compared to baseline required
    inv-135: Redemplo triglyceride threshold
    Redemplo fasting triglyceride thresholdFasting triglyceride >880 mg/dL (10 mmol/L)
    Diagnostic confirmationGenetic testing OR clinical diagnosis per guidance required to confirm FCS
    Age requirementPatient must be 18 years or older
    inv-136: Revcovi monitoring thresholds
    Revcovi monitoring targetsMaintain trough ADA activity >30 mmol/hr/L AND trough dAXP <0.02 mmol/L
    Required labsSubmit trough plasma ADA activity and trough dAXP levels with dosing/weight
    Provider attestationProvider must attest dose adjustments will be made to maintain targets
    inv-137: Teriparatide prior therapy or high fracture risk
    Teriparatide high fracture risk / prior therapyT-score <= -3.0 OR T-score <= -2.5 with a fragility fracture
    Alternative requirementOr trial/failure/intolerance to bisphosphonates (e.g., alendronate, risedronate, ibandronate + zoledronic acid) documented
    PrescriberMust be prescribed by an endocrinologist per entry
    inv-138: Tetrabenazine CYP2D6 requirement
    CYP2D6 genotype requirementCYP2D6 genotype must be provided for tetrabenazine doses >50 mg/day
    Combination exclusionMust not be used in combination with Austedo or Ingrezza
    Coverage durationCoverage duration: two years
    inv-139: Testosterone labs for hypogonadism
    Testosterone lab requirement for hypogonadismTwo morning serum total testosterone levels <300 ng/dL on separate days
    Clinical signs requiredPre‑treatment clinical signs beyond erectile dysfunction or decreased libido required (e.g., decreased energy, muscle mass loss)
    Coverage durationCoverage duration: two years
    inv-140: Serum sodium
    Serum sodium threshold for tolvaptan (hyponatremia)Serum sodium <125 mEq/L
    Dosing limitsTolvaptan dosing up to 60 mg/day for hyponatremia; up to 120 mg/day for ADPKD
    DocumentationConfirm hypervolemic or euvolemic hyponatremia and failure of fluid restriction when applicable
    inv-141: Fasting triglyceride
    Fasting triglyceride threshold (Tryngolza/Redemplo context)Greater than 880 mg/dL (10 mmol/L)
    Secondary causes exclusionProvider attestation that secondary causes of hypertriglyceridemia have been excluded
    Age requirementPatient must be 18 years or older
    inv-142: Vowst course
    Vowst treatment course12 capsules over 3 days (single treatment course)
    Prior antibiotic requirementDocument at least 2 recurrent CDI episodes (3+ total) after failure of appropriate antibiotics
    Coverage limitLimited to one treatment course; coverage duration 1 year
    inv-143: Voydeya symptomatic EVH hemoglobin threshold
    Voydeya symptomatic EVH hemoglobin thresholdHemoglobin <9.5 g/dL
    Absolute Reticulocyte Count (ARC) thresholdARC >120 x10^9/L
    PNH treatment requirementMust be actively receiving ravulizumab or eculizumab and have PNH confirmed by flow cytometry
    inv-144: Absolute Reticulocyte Count (ARC)
    Absolute Reticulocyte Count (ARC)Greater than 120 x 10^9/L
    ContextUsed with Voydeya to document symptomatic extravascular hemolysis in PNH
    Age requirementPatient must be 18 years or older
    inv-145: Vyndamax age
    Vyndamax (tafamidis) minimum age18 years or older
    ExclusionWill not be approved for primary (light‑chain) amyloidosis
    Initial documentationNYHA class I–III and imaging/biopsy/genetics or radionuclide imaging with Grade 2–3 uptake if used
    inv-146: Baseline IgE
    Baseline IgE requirement (Xolair)>= 30 IU/mL
    Use caseRequired before Xolair for asthma, food allergy, chronic urticaria, and nasal polyps
    Additional requirementsBaseline positive skin or in vitro perennial aeroallergen test (asthma) and current weight documented
    inv-147: Minimum age for ZTALMY
    Minimum age for ZTALMY (CDKL5 deficiency)>= 2 years
    Diagnostic requirementConfirmation of CDKL5 deficiency by genetic testing required
    PrescriberMust be prescribed by a neurologist
    Authorization intervals
    Initial: 1 year; Reauthorization: 2 years (requires clinical response)
    inv-345: CORTROPHIN quantity limits
    CORTROPHIN quantity limitQuantity limited to dosage as supported by the FDA‑approved label
    Initial/reauth durationsInitial per FDA label or max 3 months if unspecified; reauthorization 1 year
    Supporting documentationSupporting documentation for all prior drug trials required
    inv-346: Ebglyss (repeat) dosing limits
    Ebglyss dosing (repeat)4 doses first month, then 2 doses each month thereafter
    Reauthorization requirementDocumentation of positive clinical response required for reauth
    Prescriber requirementPrescriber must be specialist or have consulted specialist
    inv-347: Fasenra duration limits
    Fasenra authorization durationInitial: 1 year; Reauthorization: 2 years (dosing per FDA labeling)
    Dose alignmentDosing must follow FDA‑approved labeling
    Reauthorization evidenceRequire documentation of clinical benefit vs baseline
    inv-348: Ojemba oral suspension quantity
    Ojemba oral suspension quantityLimited to 1 box per 28 days
    Use conditionOral suspension coverage requires inability to swallow tablet formulation
    Authorization durationOne year authorization where specified
    inv-349: Radicava quantity limits
    Radicava quantity limits70 mL first 28 days; 50 mL every 28 days thereafter
    Initial authorizationInitial coverage limited to specified volume; reauthorization requires evidence of slowing progression
    Coverage durationOne year initial; reauth per documentation
    inv-350: Prevymis quantity limits
    Prevymis quantity limit200 days
    Indication contextPer product-specific entry; duration applied consistent with indication
    DocumentationSubmit indication and dosing as requested
    inv-351: Scemblix 20 mg and 40 mg limits
    Scemblix 20 mg limit20 mg: limit to 60 tablets per 30 days
    Scemblix 40 mg limit40 mg: limit to 240 tablets per 30 days
    Prescriber requirementMust be prescribed by or in consultation with an oncologist/hematologist
    inv-352: Tolvaptan dosing limits
    Tolvaptan daily dosing limitsUp to 60 mg/day for hyponatremia; up to 120 mg/day for ADPKD
    Coverage durationsHyponatremia: 30 days; ADPKD: 2 years
    Diagnostic documentationConfirm hypervolemic/euvolemic hyponatremia (serum sodium <125 mEq/L) or ADPKD risk of rapid progression
    inv-353: Vowst course quantity
    Vowst course quantity12 capsules per treatment course
    Course frequencyLimited to one treatment course per patient
    Coverage durationInitial coverage 1 year
    inv-354: Xifaxan quantity limits
    Xifaxan IBS‑D limitUp to three 14‑day courses
    Traveler's diarrhea limitUp to three days (requires trial/failure with azithromycin)
    SIBO exclusionCoverage for SIBO is not provided
    inv-355: Zurzuvae quantity limits
    Zurzuvae course limitLimited to one treatment course per year
    Coverage durationOne year authorization
    Age requirementPatient must be 18 years or older

    Providers must review whether administration qualifies as a Part B or Part D benefit by submitting diagnosis and administration information where indicated.

    Billing Rule

    Livtencity: no concomitant CMV antivirals; baseline CMV DNA and prior antiviral trial required

    Livtencity must not be used concomitantly with other CMV antivirals (e.g., ganciclovir, valganciclovir); baseline CMV DNA must be provided and prior antiviral trial/failure documented.

    Note

    Oxervate: ophthalmologist prescriber/consult and stage documentation required

    Oxervate must be prescribed by or in consultation with an ophthalmologist; documentation of Stage 2 or 3 neurotrophic keratitis is required for coverage.

    Note

    Pirfenidone: pulmonologist prescriber/consult and HRCT or biopsy required

    Pirfenidone requests must be prescribed by or in consultation with a pulmonologist and include HRCT confirming diagnosis (surgical lung biopsy or UIP pattern where IPF is suspected); provide reauthorization evidence of improvement.

    Note

    Redemplo: specialist prescriber and FCS confirmation required

    Redemplo must be prescribed by or in conjunction with a specialist (specialty clinic) and include FCS confirmation (fasting TG >880 mg/dL and genetic testing or clinical diagnosis).

    Note

    General site‑of‑care: office acceptable unless specialist prescriber required

    When no specific site‑of‑care restriction is listed, office administration is acceptable unless a specialist prescriber is required; always verify product entry for exceptions.

    Note

    Verquvo: cardiologist prescriber/consult and EF <45% documentation required

    Verquvo must be prescribed by or in consultation with a cardiologist; providers must submit EF <45% within 12 months and documentation of prior guideline‑directed therapies and symptomatic worsening.

    Note

    Tryngolza: specialist prescriber/consult and FCS + prior Redemplo documentation required

    Tryngolza must be prescribed by or in consultation with a cardiologist, endocrinologist, or other specialist; initial requests must include FCS confirmation and prior Redemplo trial documentation.

    Note

    Winrevair: specialist prescriber + right heart cath and prior therapy evidence required

    Winrevair for PAH must be prescribed by or in consultation with a specialist for pulmonary arterial hypertension and include right heart catheterization confirmation and prior dual‑therapy failure where applicable.

    Billing Rule

    Xolair: submit diagnosis/administration details to determine Part B vs Part D benefit

    Xolair administration coverage may be Part B or Part D depending on diagnosis and administration details; submit diagnosis and administration information to determine benefit.

    Clinical classNYHA class I–III required for initial Vyndamax coverage
    inv-282: Trial and failure
    Trial and failure definitionDefined as intolerance or inability to improve the condition on the required therapy
    Documentation expectationProviders must submit records showing duration and outcome of prior trials
    ExamplesE.g., failed one H1 antihistamine for chronic urticaria; failed ICS/LABA for severe asthma
    inv-283: Non-severe EGPA
    Non‑severe EGPA definitionAbsence of life‑ or organ‑threatening manifestations
    Use caseApplied when evaluating Fasenra eligibility for EGPA
    ReauthorizationDocumentation of clinical benefit required
    inv-284: Adult growth hormone deficiency confirmation
    Adult GHD confirmation optionsConfirmed by suboptimal response on an appropriate GH stimulation test OR persistent childhood‑onset GHD OR documented pituitary/hypothalamic disease with >=3 pituitary hormone deficiencies and low IGF‑1
    If IGF‑1 indeterminateRequire suboptimal stimulation test to confirm diagnosis
    Prescriber requirementMust be prescribed by endocrinologist/gastroenterologist/nephrologist
    inv-285: MoCD Type A
    MoCD Type A confirmationRequires genetic confirmation for Nulibry coverage
    Prescriber requirementPrescribed by or in consultation with specialist in inherited metabolic disorders
    Reauthorization evidenceDocumentation of beneficial response vs baseline required
    inv-286: PAH (WHO Group 1)
    PAH (WHO Group 1) confirmationMust be confirmed by right heart catheterization for PAH agents
    Coverage durationTypically two years unless specified otherwise
    Documentation riskLack of right heart cath documentation may trigger denial
    inv-287: ALSFRS-R
    ALSFRS‑R baseline requirementBaseline requirement of at least 2 points on each of 12 items (minimum total 24)
    Use for RadicavaUsed to document retention of activities of daily living for initial Radicava requests
    Respiratory requirement%FVC >=80% predicted also required
    inv-288: UIP pattern
    UIP pattern definitionUsual Interstitial Pneumonia (UIP) pattern on HRCT consistent with idiopathic pulmonary fibrosis
    Pirfenidone requirementHRCT or surgical lung biopsy showing UIP and exclusion of other causes required for IPF
    PrescriberPrescriber is or has consulted with a pulmonologist
    inv-289: ATTR-CM
    ATTR‑CM definitionTransthyretin amyloid cardiomyopathy confirmed by imaging (ECHO/CMR) or biopsy/genetics or radionuclide imaging with Grade 2–3 uptake
    Age/NYHAAge >=18 and NYHA class I–III for initial Vyndamax coverage
    ExclusionNot approved for primary (light‑chain) amyloidosis
    inv-290: Baseline IgE
    Baseline IgE definitionIgE level measured before treatment with Xolair or any therapy that lowers IgE levels; threshold commonly set at >=30 IU/mL
    TimingBaseline IgE must be measured prior to initiation and used for dosing/eligibility
    ApplicationsApplies to asthma, food allergy, chronic urticaria, and nasal polyps indications for Xolair
    inv-291: Index definition
    Index definitionIndex — list of drugs, formulations, pack types and page references within the multi‑part policy document
    PurposeProvides quick navigation to main policy entries where authorization rules reside
    Not authoritative for criteriaIndex entries reference rules; the detailed criteria are in product sections